Stock DNA
Pharmaceuticals & Biotechnology
CNY 20,102 Million (Large Cap)
NA (Loss Making)
NA
0.00%
-0.34
-9.85%
2.17
Revenue and Profits:
Net Sales:
955 Million
(Quarterly Results - Jun 2025)
Net Profit:
59 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.4%
0%
-12.4%
6 Months
-14.12%
0%
-14.12%
1 Year
-2.89%
0%
-2.89%
2 Years
-13.58%
0%
-13.58%
3 Years
-24.24%
0%
-24.24%
4 Years
-51.29%
0%
-51.29%
5 Years
-66.42%
0%
-66.42%
BGI Genomics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.44%
EBIT Growth (5y)
-186.74%
EBIT to Interest (avg)
3.94
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
0.43
Tax Ratio
0.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
30.08%
ROE (avg)
9.50%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.17
EV to EBIT
-17.20
EV to EBITDA
-37.80
EV to Capital Employed
2.77
EV to Sales
4.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.10%
ROE (Latest)
-9.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
954.80
1,045.40
-8.67%
Operating Profit (PBDIT) excl Other Income
124.80
132.40
-5.74%
Interest
7.90
15.10
-47.68%
Exceptional Items
2.90
-2.40
220.83%
Consolidate Net Profit
59.40
8.00
642.50%
Operating Profit Margin (Excl OI)
-5.20%
-1.80%
-0.34%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -8.67% vs -6.20% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 642.50% vs -24.53% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,847.10
4,335.90
-11.27%
Operating Profit (PBDIT) excl Other Income
-132.10
582.60
-122.67%
Interest
56.30
94.80
-40.61%
Exceptional Items
-237.50
-43.60
-444.72%
Consolidate Net Profit
-912.10
93.70
-1,073.43%
Operating Profit Margin (Excl OI)
-176.40%
25.30%
-20.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.27% vs -38.41% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -1,073.43% vs -88.42% in Dec 2023
About BGI Genomics Co., Ltd. 
BGI Genomics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






